Is ixazomib a chemotherapy drug or a targeted drug? Analysis of drug categories and treatment principles

Ixazomib is an anti-cancer drug used to treat multiple myeloma. Strictly speaking, it is a "targeted therapy drug" rather than a chemotherapy drug in the traditional sense. Its target of action is clear. It is an oral proteasome inhibitor that specifically inhibits the 26S proteasome system in cancer cells, thereby blocking the degradation pathway of intracellular proteins and inducing apoptosis of cancer cells. This precise mechanism makes it essentially different from broad-spectrum cell-killing chemotherapy drugs.

Traditional chemotherapy drugs such as alkylating agents and antimetabolites often work by destroying all rapidly dividing cells. They not only kill cancer cells, but also damage normal tissue cells, leading to side effects such as hair loss, bone marrow suppression, and gastrointestinal reactions. Ixazomib, on the other hand, mainly targets the abnormally dependent protein degradation mechanism of tumor cells and has less impact on normal cells, so the side effects are relatively mild. It is a modern anti-tumor drug with "strong targeting and low toxicity".

Ixazomib is often used in combination with lenalidomide (lenalidomide) and dexamethasone to form a standard triple therapy regimen, which is especially suitable for patients with relapsed or refractory multiple myeloma who have received at least one previous treatment regimen. The drug has been approved by the FDA and is gradually being promoted in many countries and regions. The advantages of its oral formulation also greatly improve patients' medication convenience and compliance.

In summary, although ixazomib has anti-cancer effects, it is not a traditional chemotherapy drug, but a targeted drug with clear molecular targets. It achieves therapeutic effects by selectively inhibiting proteasome activity and interfering with the survival mechanism of cancer cells. Compared with chemotherapy drugs, ixazomib has milder side effects and can be taken orally. It is an important development in the treatment of multiple myeloma in recent years.

Reference materials:https://www.ninlaro.com/